Lidocaine Jelly and Gels Market

Global Lidocaine Jelly and Gels Market by Product Types (Rx, and OTC), Applications (Interstitial Cystitis or Bladder Pain Syndrome, Pain Relief in Urethritis, Arthritis, Skin Discomfort, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

  • Report ID: HC-2606
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 1
  • No. Of Pages: 227
  • Format:
  • Pub. Date: 21-05-2021
  • Share:

Market Outlook:

The global lidocaine jelly and gels market was valued at USD 166.1 Million in 2019 and is projected to reach USD 216.5 Million by 2027, expanding at a CAGR of 3.7% during the forecast period. Demand for lidocaine jelly and gels is driven by the multiple applications such as dentistry, urology, and tattoos, growth of OTC drugs segment, rising adoption of e-pharmacies, and increasing healthcare expenditure.

Lidocaine Jelly and Gels Market Key Takeaways

Lidocaine is one of the prominent and commonly used medications used to numb the tissues. It is available in jelly, gels, injectable, spray, and others forms. It is used for facilitating anesthesia for various surgical procedures. Lidocaine numbs the tissues by blocking sodium channels, which in turn, creates an invisible barrier between the neurons of local tissues and makes them incapable of signaling the brain. It is considered as class Ib anti-arrhythmic agent owing to its varied usage such as decreasing muscle contractions, resulting in effects like hypotension, and irregular heart rate.

Market Dynamics

Lidocaine jelly is prominently used during catheter insertion. The cases related to urinary catheter insertion is rising. The Lidocaine gels is a primary product used during long catheterizations, as patients need numbness to bear long treatment schedules, which in turn, fuels the need for lidocaine gels, thereby propelling the market during the forecast period.

Lidocaine jelly helps in to manage pain caused by different chronic diseases such as arthritis, urethritis, and others. Generally, the lidocaine gel is applied externally on the skin surface which is absorbed by the skin to numb and reduce the pain in the area. Rising incidence rate of chronic diseases, especially in densely populated countries such as India and China, fuels demand for Lidocaine jelly to treat chronic diseases. According to the National Center for Biotechnology Information, 33% of population in China and 49% of people India, aged 50 years and above, have been reported with at least one chronic condition. These figures proves the high need for Lidocaine jelly, which in turn, is expected to fuel the market during the forecast period.

The FDA has raised concerns regarding the usage of Lidocaine jelly and gels usage on infants and children, especially for tooth-related pains, as this can lead to serious implications such as seizures and brain damage. Various governmental bodies have raised concerns on the over usage of OTC Lidocaine jelly, as its extensive usage can lead to methemoglobinemia. Thus, implementation of rigid government regulations are likely to restrain the global lidocaine jelly and gels market. Medical companies are developing alternative methods and products to treat ailments of individuals. Furthermore, doctors are preferring anesthetic from the ester group as Lidocaine (a classified amide) is allergic to some patients. Additionally, easy availability of Tramadol, Gabapentin, and growing number of substitutes which serve the same purpose is likely to impede the market during the forecast period. Lidocaine is a local painkiller and a primary aid for many skin remedies. Besides this, Lidocaine is extensively used in cosmetic surgeries. Increase in the number of cosmetic surgeries boosts the demand for the jelly. Surge in the number of cosmetic surgeries is likely to create lucrative opportunities for Lidocaine jelly and gel manufacturers in the coming years.

Segmental Outlook

On the basis of product types, the global lidocaine jelly and gels market has been bifurcated into Rx and OTC. The Rx segment is expected to hold a significant share of the market during the forecast period due to high adoption of prescription drugs, as prescription drugs enable patients to opt for treatments that are suitable to their health orientations and medical history. The OTC segment is anticipated to hold a key share of the market and is projected to expand at a substantial CAGR during the forecast period.

Lidocaine Jelly and Gels Market By Product Type

In terms of applications, the global lidocaine jelly and gels market has been segmented into interstitial cystitis/bladder pain syndrome, pain relief in urethritis and others. The interstitial cystitis/bladder pain syndrome segment is expected to hold a significant share of the market and is anticipated to expand at a considerable CAGR during the forecast period. The growth of this segment is attributed to the rising awareness regarding health among people and increasing incidences of bladder pain syndrome. The pain relief in urethritis segment is anticipated to account for a substantial share of the market and is projected to expand at a substantial CAGR during the forecast period. Growing usage of lidocaine gel for pain relief and rising number of cases of urethritis are boosting the segment’s growth.

Lidocaine Jelly and Gels Market By Applications

Based on distribution channels, the global lidocaine jelly and gels market has been segregated into hospital pharmacy, retail pharmacy and e-commerce. The hospital pharmacy segment is expected to hold a significant share of the market and is anticipated to expand at a considerable CAGR during the forecast period. Hospitals carry out various surgeries, procedures, and treatments that utilize lidocaine jelly such as cystoscopy, cataract surgery, and endotracheal intubation, for which they use their pharmacy’s stock of drugs. This, in turn, is fueling the hospital pharmacy segment. The retail pharmacy segment is anticipated to account for a sizeable share of the market and is projected to expand at a substantial CAGR during the forecast period, owing to the rising number of developments in remote areas, growing population, easy access to pharmacies, and increasing use of lidocaine gel for pain relief are propelling the segment.

Regional Outlook

On the basis of regions, the global job description management software market is fragmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The US holds a substantial share of the market. The market in the country is expected to expand at a considerable CAGR during the forecast period. The demand for OTC drugs is rising in the US, as stores in the country often sell private label OTC products, which are extensively used due to the lower cost than the Rx products. Italy has the highest percentage of people adopting tattoos, which in turn, is propelling the market for lidocaine jelly and gels in the country.

Lidocaine Jelly and Gels Market By Region

Key Benefits for Industry Participants & Stakeholders

  • In-depth analysis of the global lidocaine jelly and gels market
  • Historical, current, and projected market size in terms of value (USD million) and volume (tons)
  • Potential & niche segments and regions exhibiting promising growth covered Industry drivers, restraints, and opportunities covered in the study
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players

Segments

By Product Types

  • Rx
  • OTC

By Applications

  • Interstitial Cystitis or Bladder Pain Syndrome
  • Pain Relief in Urethritis
  • Arthritis
  • Skin Discomfort
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Market Players Profiled in the Report

  • Akorn Incorporated
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca
  • Curatio Healthcare Private Limited
  • ESBA Laboratories Inc.
  • FARCO-PHARMA GmbH
  • Gensco Pharma
  • Innovative Pharmaceuticals
  • Merit Pharmaceutical
  • Quest Products, Inc.
  • Septodont Healthcare India Pvt. Ltd.
  • Sidefarma

Competitive Landscape

  • Prominent manufacturers operating in the global lidocaine jelly and gels market include Akorn, Incorporated, Aspen Pharmacare Holdings Limited, AstraZeneca, Curatio Healthcare Private Limited, ESBA Laboratories Inc., and FARCO-PHARMA GmbH.
  • These companies are considered as key manufacturers of lidocaine jelly and gels based on their revenue, research & development (R&D) activities, regional presence, and supply chain management system.
Lidocaine Jelly and Gels Market By Key Players

Video Summary for Lidocaine Jelly and Gels Market

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lidocaine Jelly and Gels Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Lidocaine Jelly and Gels Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Lidocaine Jelly and Gels Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Lidocaine Jelly and Gels  Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Lidocaine Jelly and Gels Market Size & Forecast, 2017-2027
      4.5.1 Lidocaine Jelly and Gels Market Size and Y-o-Y Growth
      4.5.2 Lidocaine Jelly and Gels Market Absolute $ Opportunity

   4.6 Impact of Key Regulations
   4.7 Pipeline Analysis
Chapter 5 Global Lidocaine Jelly and Gels Market Analysis and Forecast By Product Types
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product Types
      5.1.2 Basis Point Share (BPS) Analysis By Product Types
      5.1.3 Absolute $ Opportunity Assessment By Product Types
   5.2 Lidocaine Jelly and Gels Market Size Forecast By Product Types
      5.2.1 Rx
      5.2.2 OTC
   5.3 Market Attractiveness Analysis By Product Types
Chapter 6 Global Lidocaine Jelly and Gels Market Analysis and Forecast By Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Applications
      6.1.2 Basis Point Share (BPS) Analysis By Applications
      6.1.3 Absolute $ Opportunity Assessment By Applications
   6.2 Lidocaine Jelly and Gels Market Size Forecast By Applications
      6.2.1 Interstitial Cystitis or Bladder Pain Syndrome
      6.2.2 Pain Relief in Urethritis
      6.2.3 Arthritis
      6.2.4 Skin Discomfort
      6.2.5 Others
   6.3 Market Attractiveness Analysis By Applications
Chapter 7 Global Lidocaine Jelly and Gels Market Analysis and Forecast By Distribution Channels
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Distribution Channels
      7.1.2 Basis Point Share (BPS) Analysis By Distribution Channels
      7.1.3 Absolute $ Opportunity Assessment By Distribution Channels
   7.2 Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      7.2.1 Hospital Pharmacies
      7.2.2 Retail Pharmacies
      7.2.3 E-Commerce
   7.3 Market Attractiveness Analysis By Distribution Channels
Chapter 8 Global Lidocaine Jelly and Gels Market Analysis and Forecast by Region
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities by Region
      8.1.2 Basis Point Share (BPS) Analysis by Region
      8.1.3 Absolute $ Opportunity Assessment by Region
   8.2 Lidocaine Jelly and Gels Market Size Forecast by Region
      8.2.1 North America
      8.2.2 Europe
      8.2.3 Asia Pacific
      8.2.4 Latin America
      8.2.5 Middle East & Africa (MEA)
   8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
   9.1 Introduction
   9.2 Current & Future Impact Analysis
   9.3 Economic Impact Analysis
   9.4 Government Policies
   9.5 Investment Scenario
Chapter 10 North America Lidocaine Jelly and Gels  Analysis and Forecast
   10.1 Introduction
   10.2 North America Lidocaine Jelly and Gels Market Size Forecast by Country
      10.2.1 U.S.
      10.2.2 Canada
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 North America Lidocaine Jelly and Gels Market Size Forecast By Product Types
      10.6.1 Rx
      10.6.2 OTC
   10.7 Basis Point Share (BPS) Analysis By Product Types
   10.8 Absolute $ Opportunity Assessment By Product Types
   10.9 Market Attractiveness Analysis By Product Types
   10.10 North America Lidocaine Jelly and Gels Market Size Forecast By Applications
      10.10.1 Interstitial Cystitis or Bladder Pain Syndrome
      10.10.2 Pain Relief in Urethritis
      10.10.3 Arthritis
      10.10.4 Skin Discomfort
      10.10.5 Others
   10.11 Basis Point Share (BPS) Analysis By Applications
   10.12 Absolute $ Opportunity Assessment By Applications
   10.13 Market Attractiveness Analysis By Applications
   10.14 North America Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      10.14.1 Hospital Pharmacies
      10.14.2 Retail Pharmacies
      10.14.3 E-Commerce
   10.15 Basis Point Share (BPS) Analysis By Distribution Channels
   10.16 Absolute $ Opportunity Assessment By Distribution Channels
   10.17 Market Attractiveness Analysis By Distribution Channels
Chapter 11 Europe Lidocaine Jelly and Gels  Analysis and Forecast
   11.1 Introduction
   11.2 Europe Lidocaine Jelly and Gels Market Size Forecast by Country
      11.2.1 Germany
      11.2.2 France
      11.2.3 Italy
      11.2.4 U.K.
      11.2.5 Spain
      11.2.6 Russia
      11.2.7 Rest of Europe
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Europe Lidocaine Jelly and Gels Market Size Forecast By Product Types
      11.6.1 Rx
      11.6.2 OTC
   11.7 Basis Point Share (BPS) Analysis By Product Types
   11.8 Absolute $ Opportunity Assessment By Product Types
   11.9 Market Attractiveness Analysis By Product Types
   11.10 Europe Lidocaine Jelly and Gels Market Size Forecast By Applications
      11.10.1 Interstitial Cystitis or Bladder Pain Syndrome
      11.10.2 Pain Relief in Urethritis
      11.10.3 Arthritis
      11.10.4 Skin Discomfort
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis By Applications
   11.12 Absolute $ Opportunity Assessment By Applications
   11.13 Market Attractiveness Analysis By Applications
   11.14 Europe Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      11.14.1 Hospital Pharmacies
      11.14.2 Retail Pharmacies
      11.14.3 E-Commerce
   11.15 Basis Point Share (BPS) Analysis By Distribution Channels
   11.16 Absolute $ Opportunity Assessment By Distribution Channels
   11.17 Market Attractiveness Analysis By Distribution Channels
Chapter 12 Asia Pacific Lidocaine Jelly and Gels  Analysis and Forecast
   12.1 Introduction
   12.2 Asia Pacific Lidocaine Jelly and Gels Market Size Forecast by Country
      12.2.1 China
      12.2.2 Japan
      12.2.3 South Korea
      12.2.4 India
      12.2.5 Australia
      12.2.6 South East Asia (SEA)
      12.2.7 Rest of Asia Pacific (APAC)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Asia Pacific Lidocaine Jelly and Gels Market Size Forecast By Product Types
      12.6.1 Rx
      12.6.2 OTC
   12.7 Basis Point Share (BPS) Analysis By Product Types
   12.8 Absolute $ Opportunity Assessment By Product Types
   12.9 Market Attractiveness Analysis By Product Types
   12.10 Asia Pacific Lidocaine Jelly and Gels Market Size Forecast By Applications
      12.10.1 Interstitial Cystitis or Bladder Pain Syndrome
      12.10.2 Pain Relief in Urethritis
      12.10.3 Arthritis
      12.10.4 Skin Discomfort
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis By Applications
   12.12 Absolute $ Opportunity Assessment By Applications
   12.13 Market Attractiveness Analysis By Applications
   12.14 Asia Pacific Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      12.14.1 Hospital Pharmacies
      12.14.2 Retail Pharmacies
      12.14.3 E-Commerce
   12.15 Basis Point Share (BPS) Analysis By Distribution Channels
   12.16 Absolute $ Opportunity Assessment By Distribution Channels
   12.17 Market Attractiveness Analysis By Distribution Channels
Chapter 13 Latin America Lidocaine Jelly and Gels  Analysis and Forecast
   13.1 Introduction
   13.2 Latin America Lidocaine Jelly and Gels Market Size Forecast by Country
      13.2.1 Brazil
      13.2.2 Mexico
      13.2.3 Rest of Latin America (LATAM)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Latin America Lidocaine Jelly and Gels Market Size Forecast By Product Types
      13.6.1 Rx
      13.6.2 OTC
   13.7 Basis Point Share (BPS) Analysis By Product Types
   13.8 Absolute $ Opportunity Assessment By Product Types
   13.9 Market Attractiveness Analysis By Product Types
   13.10 Latin America Lidocaine Jelly and Gels Market Size Forecast By Applications
      13.10.1 Interstitial Cystitis or Bladder Pain Syndrome
      13.10.2 Pain Relief in Urethritis
      13.10.3 Arthritis
      13.10.4 Skin Discomfort
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis By Applications
   13.12 Absolute $ Opportunity Assessment By Applications
   13.13 Market Attractiveness Analysis By Applications
   13.14 Latin America Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      13.14.1 Hospital Pharmacies
      13.14.2 Retail Pharmacies
      13.14.3 E-Commerce
   13.15 Basis Point Share (BPS) Analysis By Distribution Channels
   13.16 Absolute $ Opportunity Assessment By Distribution Channels
   13.17 Market Attractiveness Analysis By Distribution Channels
Chapter 14 Middle East & Africa (MEA) Lidocaine Jelly and Gels  Analysis and Forecast
   14.1 Introduction
   14.2 Middle East & Africa (MEA) Lidocaine Jelly and Gels Market Size Forecast by Country
      14.2.1 Saudi Arabia
      14.2.2 South Africa
      14.2.3 UAE
      14.2.4 Rest of Middle East & Africa (MEA)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Middle East & Africa (MEA) Lidocaine Jelly and Gels Market Size Forecast By Product Types
      14.6.1 Rx
      14.6.2 OTC
   14.7 Basis Point Share (BPS) Analysis By Product Types
   14.8 Absolute $ Opportunity Assessment By Product Types
   14.9 Market Attractiveness Analysis By Product Types
   14.10 Middle East & Africa (MEA) Lidocaine Jelly and Gels Market Size Forecast By Applications
      14.10.1 Interstitial Cystitis or Bladder Pain Syndrome
      14.10.2 Pain Relief in Urethritis
      14.10.3 Arthritis
      14.10.4 Skin Discomfort
      14.10.5 Others
   14.11 Basis Point Share (BPS) Analysis By Applications
   14.12 Absolute $ Opportunity Assessment By Applications
   14.13 Market Attractiveness Analysis By Applications
   14.14 Middle East & Africa (MEA) Lidocaine Jelly and Gels Market Size Forecast By Distribution Channels
      14.14.1 Hospital Pharmacies
      14.14.2 Retail Pharmacies
      14.14.3 E-Commerce
   14.15 Basis Point Share (BPS) Analysis By Distribution Channels
   14.16 Absolute $ Opportunity Assessment By Distribution Channels
   14.17 Market Attractiveness Analysis By Distribution Channels
Chapter 15 Competition Landscape
   15.1 Lidocaine Jelly and Gels  Market: Competitive Dashboard
   15.2 Global Lidocaine Jelly and Gels  Market: Market Share Analysis, 2019
   15.3 Company Profiles (Details - Overview, Financials, Developments, Strategy)
      15.3.1 Akorn, Incorporated
      15.3.2 Aspen Pharmacare Holdings Limited
      15.3.3 AstraZeneca
      15.3.4 Curatio Healthcare Private Limited
      15.3.5 ESBA Laboratories Inc.
      15.3.6 FARCO-PHARMA GmbH
      15.3.7 Gensco Pharma
      15.3.8 Innovative Pharmaceuticals
      15.3.9 Merit Pharmaceutical
      15.3.10 Quest Products, Inc.
      15.3.11 Septodont Healthcare India Pvt. Ltd.
      15.3.12 Sidefarma

By Product Types

  • Rx
  • OTC

By Applications

  • Interstitial Cystitis or Bladder Pain Syndrome
  • Pain Relief in Urethritis
  • Arthritis
  • Skin Discomfort
  • Others

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Market Players Profiled in the Report

  • Akorn Incorporated
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca
  • Curatio Healthcare Private Limited
  • ESBA Laboratories Inc.
  • FARCO-PHARMA GmbH
  • Gensco Pharma
  • Innovative Pharmaceuticals
  • Merit Pharmaceutical
  • Quest Products, Inc.
  • Septodont Healthcare India Pvt. Ltd.
  • Sidefarma
  • Prominent manufacturers operating in the global lidocaine jelly and gels market include Akorn, Incorporated, Aspen Pharmacare Holdings Limited, AstraZeneca, Curatio Healthcare Private Limited, ESBA Laboratories Inc., and FARCO-PHARMA GmbH.
  • These companies are considered as key manufacturers of lidocaine jelly and gels based on their revenue, research & development (R&D) activities, regional presence, and supply chain management system.
Lidocaine Jelly and Gels Market By Key Players

Buy Report

FAQ Section

Some frequently asked quetions about this report!

Additional company profiles are provided on request.

Yes, the report provides supply chain analysis along with a list of raw material suppliers, manufacturers, distributors, and customers.

According to the Growth Market Reports, the market for lidocaine jelly and gels is likely to register a CAGR of 3.7% during forecast period 2020-2027, with an anticipated valuation of USD 216.5 million by the end of 2027.

In addition to market size (in USD Million) and, company market share (in % for base year 2019), other data such as Impact of Key Regulations, Pipeline Analysis, macro-economic factors and COVID-19 impact on the value chain are available in the final report.

Applications in the global lidocaine jelly and gels market includes interstitial cystitis or bladder pain syndrome, pain relief in urethritis, arthritis, skin discomfort, and others.

Demand for lidocaine jelly and gels is expected to continue to increase over the forecast period, taking into account multiple applications such as dentistry, urology, and tattoos, growth of OTC drugs segment, rising adoption of e-pharmacies, and increasing healthcare expenditure.

Factors such as competitive strength and market positioning are key areas, which are considered while selecting top companies to be profiled.

The market is expected to decrease around 1.2% in 2020, owing to the negative impact of COVID-19 pandemic on the global lidocaine jelly and gels market.

The base year considered for the global lidocaine jelly and gels market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.

Major Manufactures are Akorn, Incorporated, Aspen Pharmacare Holdings Limited, AstraZeneca, Curatio Healthcare Private Limited, ESBA Laboratories Inc., and FARCO-PHARMA GmbH.